In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.
about
Emerging drugs and vaccines for candidemiaPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsComparison of echinocandin antifungalsEpidemiology of invasive candidiasis: a persistent public health problemAnidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaAntifungal pharmacokinetics and pharmacodynamicsIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Anidulafungin in the treatment of invasive fungal infections.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafunginIsavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.Paradoxical echinocandin activity: a limited in vitro phenomenon?A clinical review of echinocandins in pediatric patients.Echinocandin pharmacodynamics: review and clinical implications.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia.Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.Antifungal drugs: predicting clinical efficacy with pharmacodynamics.Newer antifungal agents.Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive Candidiasis Murine Model Using an Extended Interval Dosing Design.Pharmacology of Systemic Antifungal AgentsIn silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaosGlucan Synthase Inhibitors
P2860
Q26828993-56088B91-9F9F-46E4-8806-68874C6052ADQ27025299-0F67F3F3-F63B-4F35-BD31-754C11A3C149Q28273738-B37682D6-7A0F-4E04-B008-CDA3FD0DAE16Q29616758-EA1A8FEB-846E-4DE4-8690-BAB8CA808CB4Q33490772-1BA1D34E-E40A-4BF2-A082-164651DB81B2Q33876423-34E9404B-DA36-47B6-834D-FB2E60E307FDQ34123805-5DA89C86-EACB-4F04-A71F-3C1528335662Q34228214-E1DD17EA-FAC7-45A5-B104-60F50E186533Q34933267-3665C4BD-8058-4FD0-91BF-C4A886F719A1Q35091285-3A9324B5-6525-4F0E-9218-ED1CCBBDF109Q35105763-DF01E2D1-021A-4464-9248-07BE71D1D99FQ35185757-3C3E3DA8-8DE8-4CB5-BE4E-7B876EDBB238Q35647785-BBB80BF1-EFB6-4260-BE51-DB63AC6BCB82Q35663841-6331F55F-300A-4E21-8667-E61EA01031E7Q36425025-9F8DB37F-3D12-44B5-951C-2F552E81A83BQ36822941-C83713E5-2114-4C23-944E-9FFDC025FE1EQ36932989-6B930D47-23C3-4BD0-BE1A-92EEF5E7A3B9Q37190801-5DEE919A-643A-4CC2-9DC1-48909AB31B89Q37263435-9FA49D8C-1B8B-4380-80D1-A20032D18BA2Q37291442-77C99DC3-53D9-4062-9188-BE245158E04EQ37405284-B8753B39-FD88-41A4-82BC-2C265909062AQ37653647-7DEDAE48-57D0-42D3-A2AB-F545A18B0BD5Q37718385-6D53DF95-347E-471D-991A-C2EF654D9139Q37918556-FF037E83-EBFD-408D-988B-41FCFBCCE387Q38093135-3B9385D3-248E-4895-A213-A8ED1F453AF1Q38919690-3998020E-2BB6-44CF-8820-D68443C6D399Q40332713-DCA0F29A-6588-4F44-95FC-3F4F73AE6DFFQ40916536-1D3781E9-EB47-44F1-8068-D1A33B79A2F2Q41929256-0DC49461-F005-4D6F-BDD2-CD31A6EEF716Q42723597-452298FB-7C8E-46C7-91D2-561571F60161Q44855715-740D6A91-D05D-46E0-81A8-B2516680C3F0Q46248423-4EB891F6-5FEF-4885-9D68-2C648E775C9CQ57533011-17C5F990-9E5D-43EE-99BF-CF5071197C6BQ58033439-50CC7D19-ECBD-480B-A5D3-D4CC41EC34ADQ58033533-A59C7FF8-93E0-42DF-A9CB-DAE4DBF6179B
P2860
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@ast
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@en
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@nl
type
label
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@ast
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@en
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@nl
prefLabel
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@ast
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@en
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@nl
P2093
P2860
P1476
In vivo pharmacodynamics of HM ...... in a murine candidiasis model.
@en
P2093
P2860
P304
P356
10.1128/AAC.47.4.1187-1192.2003
P407
P577
2003-04-01T00:00:00Z